Titlebook: Bone marrow stem cell therapy for stroke; Kunlin Jin,Xunming Ji,Qichuan Zhuge Book 2017 Springer Nature Singapore Pte Ltd. 2017 bone marro

可憐

書(shū)目名稱Bone marrow stem cell therapy for stroke影響因子(影響力)




書(shū)目名稱Bone marrow stem cell therapy for stroke影響因子(影響力)學(xué)科排名




書(shū)目名稱Bone marrow stem cell therapy for stroke網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Bone marrow stem cell therapy for stroke網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Bone marrow stem cell therapy for stroke被引頻次




書(shū)目名稱Bone marrow stem cell therapy for stroke被引頻次學(xué)科排名




書(shū)目名稱Bone marrow stem cell therapy for stroke年度引用




書(shū)目名稱Bone marrow stem cell therapy for stroke年度引用學(xué)科排名




書(shū)目名稱Bone marrow stem cell therapy for stroke讀者反饋




書(shū)目名稱Bone marrow stem cell therapy for stroke讀者反饋學(xué)科排名

莊嚴(yán)

允許

propose

Interaction of Bone Marrow Stem Cells with Other Cells,nderlying functional recovery after stroke remain unclear. Clearly, BMSCs benefit the neurological dysfunction in either direct or indirect methods through the interaction with other cells. In this chapter, we review the direct and indirect interactions of transplanted BMSCs with HSCs, immune cells,

觀點(diǎn)

五行打油詩(shī)

Admonish

Endothelial Progenitor Cell Therapy in Stroke,ental animal models and clinical trials. In this review, we discussed the characteristics of EPCs in the stroke therapy. We summarized the effect of EPCs on the treatment of cerebrovascular diseases including ischemic and hemorrhagic stroke, moyamoya disease, and vascular tumor, etc. Although the mo

Infantry

Co-transplantation Strategies and Combination Therapies for Stroke,cidence of stroke increases significantly with age both in men and women with incidence rates accelerating above 70 years. Since stroke afflicts mostly the elderly comorbid patients, it is highly desirable to test the efficacy of cell therapies in an appropriate animal stroke model. All monotherapeu

散布

Modification of Bone Marrow Stem Cells for Homing and Survival During Cerebral Ischemia,sability worldwide. Various stem cells from bone marrow, such as mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and endothelial progenitor cells (EPCs), have shown therapeutic potential for stroke. Concomitant with these exciting findings are some fundamental bottlenecks that must b

APO

Clinical Studies of Bone Marrow-Derived Stem Cell Therapy in Stroke Patients,tics and endovascular thrombectomy can reduce stroke disability; however, only a small minority of patients receive these treatments. Once the neurological deficits are established, there are few options for recovery. In recent years, extensive cell therapy preclinical research has demonstrated a ne